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Rejection of donor organs depends on the trafficking
of donor passenger leukocytes to the secondary
lymphoid organs of the recipient to elicit an immune
response via the direct antigen presentation path-
way. Therefore, the depletion of passenger leuko-
cytes may be clinically applicable as a strategy to
improve graft survival. Because major histocompati-
bility complex (MHC) class IIþ cells are most efficient
at inducing immune responses, selective depletion of
this population from donor grafts may dampen the
alloimmune response and prolong graft survival. In
a fully MHC mismatched mouse kidney allograft
model, we describe the synthesis of an immuno-
toxin, consisting of the F(ab0)2 fragment of a
monoclonal antibody against the donor MHC class
II molecule I-Ak conjugated with the plant-derived
ribosomal inactivating protein gelonin. This anti–I-Ak
gelonin immunotoxin depletes I-Ak expressing cells
specifically in vitro and in vivo. When given to
recipients of kidney allografts, it resulted in indefi-
nite graft survival with normal graft function,
presence of Foxp3þ cells within donor grafts, dimin-
ished donor-specific antibody formation, and de-
layed rejection of subsequent donor-type skin grafts.
Strategies aimed at the donor arm of the immune
system using agents such as immunotoxins may
be a useful adjuvant to existing recipient-orientated
immunosuppression.
Abbreviations: BUN, blood urea nitrogen; DC, dendritic
cell; ELISpot, enzyme-linked immunospot; EYFP, en-
hanced yellow fluorescent protein; IFNg, interferon-g;
MHC, major histocompatibility complex; TLO, tertiary
lymphoid organ
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Introduction
The key initiating event during the rejection of transplanted
organs is the interaction between donor passenger
leukocytes and recipient T cells. This was first demon-
strated by a series of experimentswhere donor grafts were
depleted of passenger leukocytes by being ‘‘parked‘‘ in
primary recipients under cover of immunosuppression
before being retransplanted (1). These grafts demonstrated
prolonged survival in the secondary naive recipients, but
this beneficial effect was abrogated by administration of
donor-type dendritic cells (DCs) (2).
While modern antirejection treatments have concentrated
onmodifying the immune systemof the recipient, relatively
less work has been done on modifying that of the donor,
with very few strategies that have been developed for the
clinic. A pilot study perfusing human donor kidneys with
anti-CD45 antibodies to deplete donor passenger leuko-
cytes before transplantation resulted in a reduced incidence
of rejection (3).
Irradiation of rat livers or hearts to remove donor passenger
leukocytes before transplantation can prolong graft sur-
vival (4–6). Murine islet allografts survived in the long term
when treated more specifically with an anti-DC antibody in
vitro before transplantation (7). As donor-derived profes-
sional antigen presenting cells are invariably MHC class II
positive, attempts have been made to deplete this donor
population to prolong graft survival. Early studies using a
pan-MHC class II antibody showed slight or no prolongation
of graft survival (8–13). However, these antibodieswere not
donor specific and therefore had to be perfused through
the donor organ before transplantation rather than
the simpler method of systemic administration to the
recipient.
Studies using antidonor antibodies, including anti–MHC
class II antibodies, have yielded mixed results. In a rat
model, antidonor MHC class II antibody prolonged the
survival of heart allografts (14) and induced donor-specific
tolerance of kidney grafts (15). The antibodies did not
appear to be depleting, with the interaction between the
antibodies and the donor passenger leukocytes seemingly
imperative for this effect. In contrast, passive transfer of
donor-specific immune serum accelerated the rejection of
donor-type grafts (16).
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Strategies such as parking or irradiation of donor organs are
difficult or impossible to translate to the clinic. We aim to
use an antidonor MHC class II antibody to deliver a toxin
to donor MHC class II–expressing cells, to delete this
population in a clinically applicable manner. The use of an
immunotoxin, more commonly used in cancer therapy,
allows targeted cell death without the need for comple-
ment activation or antibody-dependent cell-mediated cyto-
toxicity associated with the use of antibodies, and the
inflammation that this may cause, which may promote
alloreactivity. We have used the plant toxin gelonin, a
ribosome inactivating protein found in the plant Gelonium
multiforum, which causes cell death by inhibiting protein
synthesis.
An MHC class II immunotoxin has previously been used
in a pancreas allograft model (17), but like the early
experiments with anti–MHC class II antibodies, this
antibody was not donor specific and therefore had to be
perfused through the pancreas before transplantation.
The limited exposure to the immunotoxin, and at a low
temperature, may have been responsible for its lack of
efficacy.
In this study, we used an antibody against a single donor
MHC class II molecule conjugated to gelonin (anti–I-Ak
gelonin immunotoxin, abbreviated as I-Ak-gelonin) to
deplete the MHC class IIþ donor passenger leukocyte
population in a fully mismatched mouse model of kidney
transplantation, to investigate the effect of this treatment
on graft survival.
Materials and Methods
Animals
All animalswere between the age of 8 and 12weeks and used in accordance
with the Animals (Scientific Procedures) Act of 1986. Female C57BL/
6CBA F1 (H-2b/k), FVB (H-2q), C57BL/6 (H-2b), CBA.Ca (H-2k), and BALB/c
(H-2d) mice were purchased from Harlan Limited (Bicester, UK). C57BL/6
mice expressing the enhanced yellow fluorescent protein (EYFP) transgene
on all cells (rosa26 promoter knockin, abbreviated as BL/6 EYFP) and BL/6
EYFPCBA F1 mice were bred in-house. All mice were kept under specific
pathogen-free conditions.
I-Ak-gelonin immunotoxin preparation
Amouse anti-mouseMHC class II I-Ak,r,f,s IgG2amonoclonal antibody (Clone
10-3.6.2, BioXCell, West Lebanon, NH) was digested into F(ab0)2 and Fc
fragments using an F(ab0)2 preparation kit (Pierce [Thermo Fisher Scientific],
Cramlington, UK) according to the manufacturer’s instructions. The F(ab0)2
fragments were conjugated to gelonin (Enzo Life Sciences, Exeter, UK) as
previously described (18). Briefly, the F(ab0)2 fragments were modified with
3-(2-pyridyldithio) propionic acid N-hydroxysuccinimide ester (Sigma,
Gillingham, UK) and incubated with a 5-fold molar excess of gelonin,
modified with 2-iminothiolane (Sigma), for 20 hours before the reaction was
terminated with 2mmol/L iodoacetamide (Sigma). Unconjugated gelonin
and F(ab0)2 fragmentswere removed via passage through aHiTrap rProtein A
FF column (SLS, Nottingham, UK) and a HiTrap Blue HP column (SLS),
respectively.
In vitro killing assay
Single-cell suspensions were obtained from spleens harvested from CBA
and BALB/c mice. Red blood cells were lysed and the splenocytes plated at
2 106 cells/mL in a 48-well plate, with either unconjugated antibody,
unconjugated F(ab0)2, or I-A
k-gelonin, all at a concentration of 400 nmol/L.
After 72 hours in culture at 378C, 5% CO2, cells were removed for flow
cytometry. Cells were stainedwith anti–I-Ek-PE (clone 14-4-4S, eBioscience,
Hatfield, UK), which recognizes the other MHC class II molecule on target
cells so that binding of I-Ak-gelonin to the target cells would not hinder the
detection of MHC class IIþ cells and a live/dead cell stain (Life Technologies,
Paisley, UK), used according to the manufacturer’s instructions. Cells were
acquired using a FACScalibur flow cytometer (BD, Oxford, UK) and analyzed
using Cellquest software version V3.3 (BD).
In vivo killing assay
The effectiveness of the I-Ak-gelonin in killing I-EKþ cells in vivowas tested.
Single-cell suspensions were obtained from spleens harvested from BL/6
EYFPCBA F1 mice. Red blood cells were lysed, and the splenocytes
were injected intravenously into recipient mice (one spleen per recipient).
I-Ak-gelonin was then injected intravenously into these mice. Spleens of
recipient mice were harvested 20 hours later, and flow cytometry was
performed as described here earlier, using only anti–I-Ek-PE antibody.
Organ transplantation
Mouse renal transplantation was performed as described previously (19).
I-Ak-gelonin was given intravenously on the day of transplant. The recipient
left native kidney was removed at the time of transplantation. The remaining
right native kidney was removed 1 week after transplantation, leaving the
donor graft life sustaining. Before and at regular intervals after the second
native nephrectomy, blood samples were obtained and measurements
of blood urea nitrogen (BUN) were made to monitor graft function, using
Infinity Urea (Microgenics [Thermo Fisher Scientific], Hemel Hempstead,
UK) according to the manufacturer’s instructions. Heart transplantation
was performed as described previously (20). Rejection of the transplanted
heart was determined by palpation and confirmed by visual inspection.
Skin transplantation was performed as described previously (21).
Histology
Periodic acid–Schiff staining was performed on 2-mm-thick paraffin sections
as previously described (22).
Immunohistochemistry
Immunohistochemistry was performed on 5-mm-thick frozen sections as
previously described (23) using an anti-Foxp3 antibody (clone FJK-16s,
eBioscience).
Donor-specific alloantibody detection
Serum from recipient mice were used for the detection of donor-specific
alloantibodies as previously described (24).
Enzyme-linked immunospot assay
Enzyme-linked immunospot (ELISpot) assays were performed as previously
described (24,25) using splenocytes harvested from heart transplant
recipients 10 days posttransplantation. Results are expressed as number
of spots per 2 105 responder cells.
Statistical analysis
Unpaired two-tailed Student’s t-tests were used for all results except
survival, which was tested by the log rank-sum test. Values are expressed
as mean standard error of mean.
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Results
I-Ak-gelonin immunotoxin kills target cells in a
specific manner in vitro
Incubation of CBA splenocytes (I-Ak expressing) with I-Ak-
gelonin for 72 hours resulted in a doubling of cell death in
the MHC class IIþ population, demonstrating its effective-
ness in vitro (Figure 1A). The killing was specific as it had no
effect non–I-Ak–expressing BALB/c cells.
Unconjugated F(ab0)2 fragments had little effect on the
death rate, while whole antibody increased the percentage
of dead cells to a similar level seen with I-Ak-gelonin.
Target cells are killed by I-Ak-gelonin immunotoxin
in vivo
BL/6 EYFPCBA F1 mice were used as splenocyte
donors as they express both the EYFP protein, which
allows tracking of donor cells in recipient mice, and the
MHC class II molecule I-Ak (inherited from the CBA parent)
that is recognized by the I-Ak-gelonin immunotoxin.
Splenocyte injection was used instead of kidney transplan-
tation here because it results in a higher number of cells that
can be tracked, giving a more accurate dose titration.
Splenocytes were injected into recipients with or without
I-Ak-gelonin treatment given intravenously, and 1 day later,
their spleens were harvested for flow cytometry. This
experiment was repeated several times with different
doses of I-Ak-gelonin. One representative experiment is
shown in Figures 1B and 1C. After injection of splenocytes
alone, 0.11% of cells express both EYFP and I-Ek.
After injection of 40 or 100mg of I-Ak-gelonin, this
population was reduced to 0.04%. The donor-derived
nontarget population (EYFPþ but negative for I-Ek) was
not affected by I-Ak-gelonin injection, at 0.03% and 0.04%
with or without immunotoxin injection, respectively. The
dose of 40mg I-Ak-gelonin was chosen for use in the kidney
transplant study.
I-Ak-gelonin immunotoxin prolongs survival of
kidney and heart allografts
To evaluate the effect of depleting donor MHC class IIþ
cells on graft survival, target antigen I-Ak–expressing
C57BL/6CBA F1 kidneys were transplanted into fully
MHC mismatched FVB recipients that do not express the
target antigen I-Ak. In naive recipients, 40% of grafts were
rejected acutely, with 40% undergoing chronic rejection
and the remaining 20% surviving long term (median
survival time 43 days; Figure 2). Graft rejection was
accompanied by a decline in graft function resulting in
an increase in BUN (Figure 3A). After one dose of 40mg
I-Ak-gelonin, administered intravenously on the day of
transplantation, 100%ofgrafts survived long term (Figure2).
BUN values in this group remained very low for the duration
of the experiment, at all times remaining lower than the long-
term survivor in the control group (Figure 3A). The difference
in graft function asmeasured by BUN is shownmore clearly
by comparing BUN at day 7, before the second native kidney
of the recipient is removed, and at day 8, 1 day after the
second nephrectomy when the graft becomes life sustain-
ing. A sharp increase was seen in the control group,
with BUN rising from 5.160.54mmol/L at day 7 to
20.64 1.77mmol/L at day 8, while the values for the
treated group were 2.8 1.03 and 4.2 1.03, respectively
(no significant difference at day 7, p¼ 0.0001 at day 8;
Figure 3B).
Donor grafts from control mice that rejected their grafts at
early time points (days 9 and 10 posttransplantation)
showed mononuclear cell infiltration, including tubulitis,
and tubular necrosis (Figure 4A). Of the controlmice that did
not reject acutely, donor grafts showed signs of chronic
tubular and glomerular damage consistent with interstitial
fibrosis and tubular atrophy (Figure 4B). Donor grafts from I-
Ak-gelonin–treated recipients, in contrast, showed well-
preserved tubules and glomeruli with little sign of damage
(Figure 4C). Mononuclear cell infiltration was in the main
restricted to tertiary lymphoid organs (TLOs) within the
donor graft (Figure 4D). In the long-term survivor of the
control group, the TLOs were less defined and there was
more infiltrate outside of these structures (Figure 4E).
Foxp3 staining of donor grafts from I-Ak-gelonin–treated
recipients revealed the presence of regulatory T cells
concentrated within these TLOs (Figure 4F), suggesting
regulation of the alloimmune response.
I-Ak-gelonin was also tested in a heart transplantation
model, using the same donor–recipient strain combination.
Treatment of recipients with I-Ak-gelonin led to a slight
prolongation of heart graft survival from a median survival
time of 17.5 to 31.5 days (n¼ 4).
To ensure that the effect seen is donor specific, I-Ak-
gelonin was administered to FVB recipients of C57BL/6
hearts, which do not express I-Ak and whose passenger
leukocytes should therefore not be depleted by the
immunotoxin. Treatment of recipients with I-Ak-gelonin
had no effect on graft survival (median survival time
11 days vs 10 days for treated and control groups,
respectively, n¼3).
Prolonged survival of challenge skin grafts
expressing donor MHC molecules regardless of
immunotoxin specificity
FVB recipients of C57BL/6CBA F1 kidney transplants
treatedwith I-Ak-geloninwere given challenge skin grafts at
around 100 days posttransplantation. The original donor
strain, C57BL/6CBAF1, the twoparental strainsC57BL/6
and CBA (not expressing and expressing I-Ak recognized
by the immunotoxin, respectively), as well as third-party
BALB/c mice were used as donors. C57BL/6CBA F1
donor skin showed prolonged survival (median survival time
of 18 vs 12 days in kidney recipients vs naive, respectively,
p¼ 0.0224; Figure 5A). C57BL/6 and CBA skin allografts
Immunotoxin in Murine Kidney Allograft
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Figure 1: Immunotoxin killing of target cells. (A) CBA splenocytes, which express the target MHC class II molecule, and BALB/c
splenocytes, which do not, were incubatedwith either I-Ak-gelonin, unconjugated F(ab0)2 fragments, or unconjugated antibody. I-A
k-gelonin
and unconjugated antibody doubled the percentage of dead CBA cells after 72 hours of incubation, while unconjugated F(ab0)2 fragments
had no effect. BALB/c cells were not killed. (B, C) Immunotoxin killing of target cells in vivo. BL/6 EYFPCBA F1 splenocytes were injected
into recipient mice with either no treatment (top FACS plot, B), 40mg I-Ak-gelonin (bottom FACS plot, B), or 100mg I-Ak-gelonin. The target
I-Ek–expressing EYFPþ splenocyte population decreased after administration of I-Ak-gelonin, while the nontarget I-Ek-EYFPþ did not (C).
Brown et al
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also had slightly prolonged survival in kidney recipients
compared with naive mice, with median survival times of
17 versus 14 days (Figure 5B) and 16 versus 12.5 days
(Figure 5C), respectively, but this did not reach statistical
significance. No extended survival of third-party BALB/c
skin grafts was observed (Figure 5D).
Decreased donor-specific alloantibody levels in
I-Ak-gelonin–treated kidney recipients
Donor-specific antibody titers were measured in serum
taken from recipients 100 days after transplantation. Much
higher titers of donor-specific antibody were seen in serum
from the untreated recipient compared with the two
recipients treated with I-Ak-gelonin when either the original
donor strain C57BL/6CBAF1 or either parental strainwas
used as target cells (Figure 6).
Alloimmune response after I-Ak-gelonin treatment
Heart grafts and spleens from I-Ak-gelonin–treated or
control FVB recipients of C57BL/6CBA F1 heart trans-
plants were harvested 10 days after transplantation to
quantify the alloimmune response to determine if it was
affected by immunotoxin treatment.
Sections of the transplanted heart were stained for Foxp3
expression. The number of Foxp3þ cellswas slightly but not
significantly higher in I-Ak-gelonin–treated grafts compared
with controls (5.35 2.16 vs 4.89 1.25 cells per high-
power field, respectively).
Splenocytes from treated and control FVB recipients of
C57BL/6CBA F1 heart transplants were used in ELISpot
assays to detect interferon-g (IFNg) production in response
to either alloantigen presented via the indirect pathway only
(using lysed donor splenocytes as stimulator cells) or
alloantigen presented by both the direct and indirect
pathways (using intact donor splenocytes as stimulator
cells). Because DCs were not removed from the recipient
splenocyte preparation, an IFNg response was seen even
without the addition of donor cells as stimulators but with
no differences between control and I-Ak-gelonin–reated
splenocytes (19.52.08 and 15.5 3.73 spots/2 105
cells, respectively). This was probably due to the indirect
pathway, because by the time point chosen (day 10
posttransplantation) we would expect most donor passen-
ger leukocytes to have been killed. The addition of donor
cells as stimulators resulted in an increase in IFNg
production through the direct pathway in both control and
I-Ak-gelonin–treated groups (24.172.86 and 271.28
spots/2 105 cells, respectively), while no or very little
increase was seen when third-party cells were used as
stimulators (17.922.26 and 21.671.94 spots/2 105
cells, respectively) (Figure 7A).When using lysed stimulator
cells, no increase in IFNg production was seen, probably
due to the fact that the indirect pathway was already in
action within the recipient splenocyte population. In fact,
a small reduction was seen when lysed stimulator cells
were used (Figure 7B).
Discussion
Given the importance of donor passenger leukocytes in the
alloimmune response, it makes sense to develop strategies
Figure 2: Survival of FVB recipients of C57BL/6CBA F1
kidneys, with or without treatment with 40mg I-Ak-gelonin.
Without treatment, mice had a median survival time of 43 days
(n¼5).With treatment, all mice survived long -term (n¼4) (median
survival time >100 days, p¼0.0262).
Figure 3: Graft function of kidney allografts after
immunotoxin treatment. (A) BUN of FVB recipients of C57BL/
6CBA F1 kidneys, with or without treatment with 40mg I-Ak-
gelonin. (B) Comparison of BUN at day 7 posttransplantation,
before the second native nephrectomy, and at day 8
posttransplantation, 1 day after the second native nephrectomy,
when the graft becomes life-sustaining. A considerable increase in
the BUN of the no-treatment group was seen but not in the I-Ak-
gelonin–treated group (p¼0.0001 at day 8).
Immunotoxin in Murine Kidney Allograft
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to deplete them to improve graft survival, such as using
monoclonal antibodies or immunotoxins. Antibodies have
the advantage of allowing specific depletion of the target
cell populations and are already being routinely used in
the clinic to deplete or modify recipient cells  (e.g.
alemtuzumab to deplete CD52þ cells), but antibodies cause
cell death through complement activation or antibody-
dependent cell-mediated cytotoxicity, both of which cause
inflammation. When used to target donor cells, this has
the potential to exacerbate the alloimmune response.
Immunotoxins combine the specificity of antibodies with
killing by toxin delivery, which may avoid these potential
problems.
Although immunotoxins were developed as a cancer
therapy and are much more commonly used in this setting,
immunotoxins have been used in transplantation. An anti-
CD3 antibody combined with diphtheria toxin has been
successfully used in primates to deplete recipient T cells
(26). Several immunotoxins have also been used to deplete
donor T cells to prevent graft-versus-host disease after
bone marrow transplantation (27,28).
Gelonin, the ribosome-inactivating protein used here, is
unable toenter cells in itsunconjugated form. Instead, it relies
on antibody internalization for delivery into the cytoplasm
and therefore is highly specific. To avoid complement
activation and antibody-dependent cell-mediated cytotoxic-
ity, the antibody used here was digested to remove the Fc
portion responsible for complement activation and binding
to leukocytes, leaving only the antigen-binding F(ab0)2
component.
TheC57BL/6CBAF1 to FVB kidney transplantmodelwas
chosen to study the effect of I-Ak-gelonin on graft survival
due to the range of outcomes seen, allowing the
immunotoxin’s effect on both acute and chronic rejection
and on long-term survival to be studied. The use of F1
donors also enabled us to use either parental strain as
challenge graft donors.
Long-term graft survival was seen in treated kidney
recipients, while heart recipients showed a modest
prolongation of survival. This may be because heart grafts
are more immunogenic than kidney grafts. As the
immunotoxin would not have depleted donor passenger
leukocytes immediately, the initial exposure of the immune
systemof the recipientmay have resulted in the rejection of
the heart grafts, albeit at a delayed tempo. Kidney grafts
however, aremore ‘‘tolerogenic,’’ and the reduced immune
Figure 4: Periodic acid–Schiff staining of
sections of kidney allografts. (A) Untreated
kidney allograft rejected at day 9 posttransplan-
tation, showing mononuclear cell infiltration,
including tubulitis (arrow), and tubular necrosis
(200 magnification). (B) Representative exam-
ples of histological changes seen in donor grafts
in untreated recipients. Three donor grafts were
examined histologically from recipients that did
not reject their grafts acutely. Interstitial fibrosis
and tubular atrophy were seen (100 magnifica-
tion). (C) I-Ak-gelonin–treated kidney allograft at
day 147 posttransplantation, showing back-to-
back tubules and little damage to the kidney
(200 magnification). (D) Tertiary lymphoid
organ formation in I-Ak-gelonin–treated kidney
allograft (100 magnification). (E) Tertiary lym-
phoid organs are much less well defined in
long-term surviving untreated kidney allograft
(100 magnification). (F) Foxp3þ cells in tertiary
lymphoid organs of I-Ak-gelonin–treated kidney
allografts (400 magnification).
Brown et al
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response resulting from the immunotoxin treatment may
have been sufficient to induce indefinite graft survival.
Long-term acceptors of kidney grafts demonstrated
prolonged survival of donor-type skin grafts, but their
survival was not indefinite. This is not surprising because
skin is far more immunogenic than kidney grafts, and it is
not unusual to observe split tolerance. In addition, skin-
specific antigens may also play a role here.
Tolerance was clearly not induced in the heart transplant
model. If translated to the clinic, immunotoxin treatment
would not be a means to induce indefinite graft survival
but may be a useful adjuvant to prevent rejection. Because
it is donor specific, the risk of opportunistic infections and
malignancies should not be increased.
In the kidney transplant model, we did observe indefinite
graft survival. It has been shown that donor passenger
leukocytes are essential for tolerance induction (29,30).
Our observation is not in discordance with this. First, the
depletion was not immediate. The reduced number (but
not absence) of donor passenger leukocytes may have
resulted in an immune reaction that was not fully effective,
leading to a dampened immune response. Second, in the
kidney graft model, the graft itself may have ‘‘tolergenic’’
properties to induce long-term survival independent of
donor passenger leukocytes.
The indefinite survival induced in kidney transplant recip-
ients suggests that the immunotoxin itself is unlikely to
have any detrimental effects on the graft and can protect it
from the rejection process. Mouse endothelial cells can
upregulate MHC class II following transplantation (31).
Therefore, donor grafts could be vulnerable to immuno-
toxin-mediated depletion. However, we have not observed
any detrimental effects. This may be due to the short half-
life of the immunotoxin, which may have been removed
from the circulation by the time MHC class II is expressed
on endothelial cells. The constitutive expression of MHC
class II molecules by human endothelial cells may hamper
the translation of this technique to the clinic. Strategies to
selectively direct the immunotoxin toward donor passenger
leukocytes while sparing endothelial cells will be required.
These are currently being developed in our laboratory.
Because the I-Ak-gelonin depletes donor passenger leuko-
cytes, it dampens the direct pathway of allorecognition.
Due to this interference with the direct pathway of
Figure 5: Survival of challenge skin grafts. Skin fromC57BL/6CBA F1 donors (A), C57BL/6 (B), and CBA (C) parental strain donors and
third party BALB/c donors (D) was transplanted onto FVB recipients of C57BL/6CBA F1 kidney transplants and I-Ak-gelonin, around
100 days posttransplantation, and naive FVBmice. C57BL/6CBA F1 donor skin showed prolonged survival [median survival time of 18 vs
12 days in kidney recipients vs naive, respectively, p¼0.0224 (A)]. C57BL/6 and CBA skin allografts also had slightly prolonged survival in
kidney recipients comparedwith naive mice, with median survival times of 17 versus 14 days (B) and 16 versus 12.5 days (C), respectively,
but this did not reach statistical significance. No extended survival of third-party BALB/c skin graftswas observedwithmedian survival times
of 13.5 days in kidney recipients compared with 12 days in naive mice (D).
Immunotoxin in Murine Kidney Allograft
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allorecognition, it might have been expected that the I-Ak-
gelonin would have an effect on acute rejection, which is
thought to primarily be caused by the direct pathway, but no
effect on chronic rejection, which is thought to bemediated
mainly by the indirect pathway. However, I-Ak-gelonin
administration prevented both acute and chronic rejection
and instead induced long-term survival of the kidney grafts
and extended the survival of challenge skin grafts. This may
be due to the fact that the direct pathway of allorecognition
is the first to appear and is the bigger response in terms
of the percentage of T cells that can recognize foreign
MHC class II directly [estimated at between 1% and 7% of
T cells (32,33)]. The dampening of the adaptive immune
response against the graft may allow this process to
be controlled by cells such as regulatory T cells, which are
mainly, if not all, of indirect specificity (34) and therefore
should be unaffected by the I-Ak-gelonin. The presence of
Foxp3þ cells [which have previously been shown to
be important in spontaneous acceptance of kidney
allografts (35,36)] within the donor grafts after treatment
with I-Ak-gelonin is in agreement with this. However, there
was very little difference between the number of Foxp3þ
cells seen in heart grafts 10 days after transplantation in
treatment and control groups. This may be because heart
grafts are more immunogenic, and therefore any beneficial
effect of the immunotoxin is not as obvious.
Figure 6: Donor-specific alloantibody detection in serum from
kidney allograft recipients. Splenocytes from C57BL/6CBA F1
(A), C57BL/6 (B), and CBA (C) mice were incubated with serum
from untreated and I-Ak-gelonin–treated kidney recipients taken at
100 days posttransplantation. Naive FVB serum was used as a
control. An anti-IgG FITC then detected the percentage of target
splenocytes that had bound donor-specific alloantibodies from
the serum. The percentages of these splenocytes positive for
alloantibody from serum from I-Ak-gelonin–treated kidney allograft
recipients were much lower than for serum from the untreated
recipient. The percentages of splenocytes that bound alloantibody
decreased with dilution of serum.
Figure 7: IFNg production by splenocytes from I-Ak-gelonin–
treated or control heart allograft recipients harvested 10 days
after transplantation. Recipient splenocytes were stimulated
with either whole donor splenocytes (A), to measure the total
alloresponse, or lysed donor splenocytes (B), to measure the
indirect pathway only. No differences between control and treated
groups were found.
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In an attempt to determine the effect of I-Ak-gelonin on the
direct and indirect pathways separately, ELISpot assays
were performed in which either whole donor splenocytes
were used, meaning antigen could be presented by both
direct and indirect pathways, or lysed donor splenocytes
were used, meaning antigen could be presented only
by the indirect pathway (25). No differences were seen
between I-Ak-gelonin–treated and control groups. This
may be due to the time point chosen (10 days post-
transplantation), which may be too late to detect any effect
of the I-Ak-gelonin treatment. Also, the ELISpots were
carried out on heart transplant recipients, which were less
sensitive to I-Ak-gelonin treatment.
Treatment with I-Ak-gelonin did reduce the level of
circulating donor-specific antibodies in kidney recipients,
presumably because of a reduction in the number of
alloantigens available. However, the presence of circulating
donor-specific antibodies, albeit at lower levels, in I-Ak-
gelonin–treated recipients of kidney allografts suggests an
active immune interaction with the graft, as does the
presence of TLOs within these grafts. In a long-term
surviving DBA/2 to C57BL/6 model of kidney transplanta-
tion, the presence of donor-specific antibodies does not
affect graft function (unpublished information) and TLO
formation is indirectly proportional to BUN (37). The
evidence for an ongoing immune response without
concomitant poor graft function or histological signs of
rejection suggests a dynamic interaction between the
regulatory and effector arms of the alloimmune response in
I-Ak-gelonin–treated recipients.
Our data suggest that depletion of donor passenger
leukocytes, resulting in indefinite kidney graft survival and
good graft function, can be achievedwith a single treatment
of an antidonor MHC class II immunotoxin administered to
the recipient after transplantation. Current antirejection
treatment is almost exclusively directed against the
immune response of the recipient. The approach described
here, directed specifically against cells of donor origin,
opens a new, simple, and safe therapeutic avenue that can
be used in conjunction with conventional therapy.
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